Promentis Pharmaceuticals: Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

(marketscreener.com) MILWAUKEE, Nov. 16, 2018 /PRNewswire/ -- Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced it has completed Phase 1 single ascending dose and multiple ascending dose studies for its lead compound, SXC-2023. SXC-2023 has...http://www.marketscreener.com/news/Promentis-Pharmaceuticals-Announces-Successful-Completion-of-Phase-1-Studies-for-SXC-2023-Targeting--27619110/?utm_medium=RSS&utm_content=20181116